Acquired hemophilia A

Hematology

Volumn 11, Issue 2, 2006, Pages 119-125

  Franchini, Massimo ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Acquired; Bleeding; Factor VIII; Hemophilia; Treatment

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALPHA INTERFERON; AUTOANTIBODY; AZATHIOPRINE; BLOOD CLOTTING FACTOR 8; CD20 ANTIBODY; CHLORAMPHENICOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DEOXYADENOSINE DERIVATIVE; FLUDARABINE; IMMUNOGLOBULIN; MERCAPTOPURINE; METHYLDOPA; METHYLPREDNISOLONE; PENICILLIN DERIVATIVE; PENICILLIN G; PHENYTOIN; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; SULFAMIDE DERIVATIVE; VINCRISTINE; BLOOD CLOTTING INHIBITOR; CD20 ANTIGEN; MONOCLONAL ANTIBODY; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANTIBODY TITER; AUTOIMMUNE DISEASE; BLEEDING DISORDER; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; EARLY DIAGNOSIS; HEMATOLOGIC MALIGNANCY; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MORBIDITY; MORTALITY; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOLID TUMOR; THROMBOPLASTIN TIME; ANTIBODY PRODUCTION; B LYMPHOCYTE; CARDIOGENIC SHOCK; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEMATOLOGIC DISEASE; HEMOPHILIA; HEMOSTASIS; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LYMPHOMA; RISK BENEFIT ANALYSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

AUTOIMMUNE DISEASES; FACTOR VIII; HEMOPHILIA A; HUMANS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; BLOOD COAGULATION DISORDERS; CHILD; CHILD, PRESCHOOL; HEMOSTASIS; IMMUNOLOGIC FACTORS; INFANT; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 33747109787     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330600574185     Document Type: Review

References (102)

1. Cohen, AJ and Kessler, CM. (1996) Acquired inhibitors Bailleres Clin Haematol, 9, pp. 331-354.
2. Morrison, AE. (1995) Acquired haemophilia and its management Br J Haematol, 89, pp. 231-236.
3. Hay, CRM. (1998) Acquired haemophilia Bailleres Clin Haematol, 11, pp. 287-303.
4. Sultan, Y. (1997) Acquired hemophilia and its treatment Blood Coagul Fibrinolysis, 8(1 Suppl), pp. 15S-18S.
5. Boggio, LN and Green, D. (2001) Acquired hemophilia Rev Clin Exp Hematol, 5, pp. 389-404.
6. Pruthi, RK and Nichols, WL. (1999) Autoimmune factor VIII inhibitors Curr Opin Hematol, 6, pp. 314-322.
7. Hay, CRM and Baglin, TP and Collins, PW and Hill, FGH and Keeling, DM. (2000) The diagnosis and management of factor VIII and IX inhibitors: A guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO) Br J Haematol, 111, pp. 78-90.
8. Green, D and Lechner, K. (1981) A survey of 215 non-hemophilic patients with inhibitors to factor VIII Thromb Haemost, 45, pp. 200-203.
9. Lottenberg, R and Kentro, TB and Kitchens, CS. (1987) Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy Arch Intern Med, 147, pp. 1077-1081.
10. Bossi, P and Cabane, J and Ninet, J and (1998) Acquired haemophilia due to factor VIII inhibitors in 34 patients Am J Med, 105, pp. 400-408.
11. Yee, TT and Pasi, KJ and Lilley, PA and Lee, CA and Factor, VIII. (1999) inhibitors in haemophiliacs: A single-centre experience over 34 years, 1964-97 Br J Haematol, 104, pp. 909-914.
12. Yee, TT and Taher, A and Pasi, KJ and Lee, CA. (2000) A survey of patients with acquired hemophilia in a hemophilia centre over a 28-year period Clin Lab Haematol, 22, pp. 275-278.
13. Di Bona, E and Schiavoni, M and Castaman, G. (1997) Acquired hemophilia: Experience of two Italian centres with 17 new cases Haemophilia, 3, pp. 183-188.
14. Morrison, AE and Ludlam, CA and Kessler, C. (1993) Use of porcine factor VIII in the treatment of patients with acquired hemophilia Blood, 81, pp. 1513-1520.
15. Hay, CRM and Negrier, C and Ludlam, CA. (1997) The treatment of bleeding in acquired hemophilia with recombinant factor VIIa: A multicenter study Thromb Haemost, 78, pp. 3-7.
16. Delgado, J and Yimenez-Yuste, V and Hernandez-Navarro, F and Villar, A. (2003) Acquired haemophilia: Review and meta-analysis focused on therapy and prognostic factors Br J Haematol, 121, pp. 21-35.
17. Solymoss, S. (1998) Postpartum acquired factor VIII inhibitors: Results of a survey Am J Haematol, 59, pp. 1-4.
18. Kashyap, R and Choudhry, VP and Mahapatra, M and Chumber, S and Saxena, R and Kaul, HL. (2001) Postpartum acquired haemophilia: Clinical recognition and management Haemophilia, 7, pp. 327-330.
19. Mazzucconi, MG and Bizzoni, L and Giorgi, A and (2001) Postpartum inhibitor to factor VIII: Treatment with high-dose immunoglobulin and dexamethasone Haemophilia, 7, pp. 422-427.
20. Hauser, I and Schneider, B and Lechner, K. (1995) Post-partum factor VIII inhibitors: A review of the literature with special reference to the value of steroid and immunosuppressive treatment Thromb Haemost, 73, pp. 1-5.
21. Kadir, RA and Koh, MB and Lee, CA and Pasi, KJ. (1997) Acquired haemophilia, an unusual cause of severe postpartum haemorrhage Br J Obstet Gynaecol, 104, pp. 854-856.
22. Baudo, F and de Cataldo, F. (2003) Acquired factor VIII inhibitors in pregnancy: Data from the Italian Haemophilia Register relevant to clinical practice Br J Obstet Gynaecol, 110, pp. 311-314.
23. Baudo, F and de Cataldo, F. (2002) Acquired factor VIII and IX inhibitors: Survey of the Italian Haemophilia Centers (AICE). Register of acquired factor VIII/IX inhibitors Haematologica, 87, pp. 22-28.
24. Ries, M and Wolfel, D and Maier-Brandt, B. (1995) Severe intracranial hemorrhage in a newborn infant with transplacental transfer of an acquired factor VIII:C inhibitor J Pediatr, 127, pp. 649-650.
25. Schulman, S and Langevitz, P and Livneh, A and Martinovitz, U and Seligsohn, U and Varon, D. (1996) Cyclosporin therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus Thromb Haemost, 76, pp. 344-346.
26. Trotta, F and Baiocchi, G and La Corte, R and Moratelli, S and Sun, LY. (1999) Long-lasting remission and successful treatment of acquired factor VIII inhibitors using cyclophosfamide in a patient with systemic lupus erythematosus Rheumatology, 38, pp. 1007-1009.
27. Soriano, RM and Mathews, JM and Guerado-Parra, E. (1987) Acquired haemophilia and rheumatoid arthritis Br J Rheumatol, 26, pp. 381-383.
28. Struillou, L and Fiks-Sigaud, M and Barrier, JH and Blat, E. (1993) Acquired haemophilia and rheumatoid arthritis: Success of immunoglobulin therapy J Intern Med, 233, pp. 304-305.
29. Dannhauser, D and Casonato, A and Pietrogrande, F and (1994) Acquired factor VIII:C inhibitor in a patient with Sjögren's syndrome: Successful treatment with steroid and immunosuppressive therapy Acta Haematol, 91, pp. 73-76.
30. Vignes, S and Le Moing, V and Meekel, P and Papo, T and Wechsler, B and Godeau, P. (1996) Acquired hemophilia: A rare complication of Sjögren's syndrome Clin Exp Rheumatol, 14, pp. 559-560.
31. Meiklejohn, DJ and Watson, HG. (2001) Acquired haemophilia in association with organ-specific autoimmune disease Haemophilia, 7, pp. 523-525.
32. Sievert, R and Goldestein, ML and Surks, MI. (1996) Graves' disease and autoimmune factor VIII deficiency Thyroid, 6, pp. 245-247.
33. Dentale, N and Fulgaro, C and Guerra, L and Fasulo, G and Mazzetti, M and Fabbri, C. (1997) Acquisition of factor VIII inhibitor after acute hepatitis C virus infection Blood, 90, pp. 3233-3234.
34. O'Reilly, RA and Hamilton, RD. (2002) Acquired haemophilia, meningioma and diphenylhydantoin therapy J Neurosurg, 53, pp. 600-605.
35. Sallah, S and Wan, JY. (2001) Inhibitors against factor VIII associated with the use of interferon-alpha and fludarabine Thromb Haemost, 86, pp. 1119-1121.
36. Regina, S and Colombat, P and Fimbel, B and Guerois, C and Gruel, Y. (2001) Acquired inhibitor to factor VIII in a patient with Hodgkin's disease following treatment with interferon-alpha Haemophilia, 7, pp. 526-527.
37. Mauser-Bunschoten, EP and Damen, M and Reesink, HW and Roosendal, G and Chamuleau, RA and van der Berg, HM. (1996) Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C Ann Intern Med, 125, pp. 297-299.
38. Tiplady, CW and Hamilton, PJ and Galloway, MJ. (2000) Acquired haemophilia complicating the remission of a patient with high grade non-Hodgkin's lymphoma treated by fludarabine Clin Lab Haem, 22, pp. 163-165.
39. Sallah, S and Singh, P and Hanrahan, LR. (1998) Antibodies against factor VIII in patients with solid tumors: Successful treatment of cancer may suppress inhibitor formation Haemostasis, 28, pp. 244-249.
40. Hauser, I and Lechner, K. (1999) Solid tumors and factor VIII antibodies Thromb Haemost, 82, pp. 1005-1007.
41. Sallah, S and Wan, JY. (2001) Inhibitors against factor VIII in patients with cancer Cancer, 91, pp. 1067-1074.
42. Sohngen, D and Specker, C and Bach, D and (1997) Acquired factor VIII inhibitors in nonhemophilic patients Ann Hematol, 74, pp. 89-93.
43. Hultin, MB. (1991) Acquired inhibitors in malignant and nonmalignant disease states Am J Med, 91, pp. 9-13.
44. Lionnet, F and Pulik, M and Genet, P and Lucas, G and Sollet, JP. (1995) Acquired factor VIII inhibitor associated with a prostate cancer: Simultaneous occurrence and healing Thromb Haemost, 73, pp. 327-328.
45. Neilson, RF and Walker, ID and Roberson, M and Factor, VIII. (1993) inhibitor associated with hepatocellular carcinoma Clin Lab Haematol, 15, pp. 145-148.
46. Shurafa, M and Raman, S and Wollner, I. (1995) Disappearance of factor VIII antibody after removal of primary colon adenocarcinoma Am J Hematol, 50, pp. 149-150.
47. Sallah, S and Nguien, NP and Abdallah, JM and Hanrahan, LR. (2000) Acquired hemophilia in patients with hematologic malignancies Arch Pathol Lab Med, 124, pp. 730-734.
48. Kesley, PR and Leyland, MJ. (1982) Acquired inhibitor to human factor VIII associated with paraproteinemia and subsequent development of chronic lymphocytic leukemia Br J Med, 285, pp. 174-176.
49. Kazmi, MA and Pickering, W and Smith, MP and Holland, LJ and Savidge, GF. (1998) Acquired haemophilia A: Errors in the diagnosis Blood Coagul Fibrinolysis, 9, pp. 623-628.
50. Taher, A and Abiad, R and Uthman, I. (2003) Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance Lupus, 12, pp. 854-856.
51. Verbruggen, B and Novakova, I and Wessels, H and Boezeman, J and van den Berg, M. (1995) Mauser-Bunshoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: Improved specificity and reliability Thromb Haemost, 73, pp. 247.
52. Scandella, D and Nakai, H and Felch, M and (2001) In hemophilia A and autoantibody inhibitor patients: The factor VIII A2 domain and light chain are most immunogenic Thromb Res, 101, pp. 377-385.
53. Green, D and Blanc, J and Foiles, N. (1999) Spontaneous inhibitors of factor VIII: Kinetics of inactivation of human and porcine factor VIII J Lab Clin Med, 133, pp. 260-264.
54. Delgado, J and Villar, A and Jimenez-Yuste, V and Gago, J and Quintana, M and Hernandez-Navarro, F. (2002) Acquired hemophilia: A single-center survey with emphasis on immunotherapy and treatment-related side-effects Eur J Haematol, 69, pp. 158-164.
55. Ludlam, CA and Morrison, AE and Kessler, C. (1994) Treatment of acquired hemophilia Semin Hematol, 31, pp. 16-19.
56. Shapiro, A. (2001) Inhibitor treatment: State of the art Semin Hematol, 38, pp. 26-34.
57. Kessler, CM. (2000) Acquired factor VIII autoantibody inhibitors: Current concept and potential therapeutic strategies for the future Haematologica, 85(Suppl), pp. 57-63.
58. Ingerslev, J. (2000) Strategies for the treatment of inhibitor patients Haematologica, 85, pp. 15-20.
59. Mudad, R and Kane, WH. (1993) DDAVP in acquired haemophilia A: Case report and review of the literature Am J Hematol, 43, pp. 295-299.
60. Gandini, G and Franchini, M and Manzato, F and Lippi, G and Aprili, G. (1999) A successful combination of prednisone, high-dose intravenous immunoglobulin and desmopressin in the treatment of acquired haemophilia A with high-titer inhibitor Haematologica, 84, pp. 1054.
61. Kessler, CM and Ludlam, CA. (1993) The treatment of acquired factor VIII inhibitors: World-wide experience with porcine factor VIII concentrate Semin Hematol, 30, pp. 22-27.
62. Hay, CRM and Bolton-Maggs, P. (1991) Porcine factor VIIIC in the management of patients with factor VIII inhibitors Trans Med Rev, 5, pp. 145-151.
63. Charles, RMH. (2000) Porcine factor VIII: Past, present and future Haematologica, 85(Suppl), pp. 21-25.
64. Sjamsoedin, LJM and Heijnen, L and Mauser-Bunschoten, EP and (1981) The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII N Engl J Med, 305, pp. 717-721.
65. Hilgartner, MW and Knatterud, GL. (1983) Feiba Study Group. The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors Blood, 61, pp. 36-40.
66. Leissinger, CA. (1999) Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors Haemophilia, 5(suppl.3), pp. 25-32.
67. Hedner, U and Glazer, S and Falch, J. (1993) Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders Transfus Med Rev, 7, pp. 78-83.
68. Roberts, HR. (1999) The use of agents that by-pass factor VIII inhibitors in patients with hemophilia Vox Sang, 77(suppl. 1), pp. 38-41.
69. Hedner, U and Erhardtsen, E. (2002) Potential role for rFVIIa in transfusion medicine Transfusion, 42, pp. 114-124.
70. Liebman, HA and Chediak, J and Fink, KI and Galvez, AG and Shah, PC and Sham, RL. (2000) Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII Am J Hematol, 63, pp. 109-113.
71. Hay, CRM and Negrier, C and Ludlam, CA. (1997) The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicenter study Throm Haemost, 78, pp. 1463-1467.
72. Franchini, M and Capra, F and Capelli, C and de Maria, E and Lippi, G and Gandini, G. (2001) Clinical efficacy of recombinant activated factor VII (rFVIIa) during acute bleeding episode and surgery in a patient with acquired hemophilia A with high inhibitor titer Haematologica, 86, pp. E12.
73. Papadaki, HA and Xylouri, I and Valatas, W and Petinarakis, J and Kontopoulou, I and Eliopoulos, GD. (1997) Severe acquired hemophilia A successfully treated with activated recombinant human factor VII Ann Hematol, 77, pp. 123-125.
74. Siddiqui, MAA and Scott, LJ. (2005) Recombinant factor VIIa (eptacog alfa): A review of its use in congenital or acquired haemophilia and other congenital bleeding disorders Drugs, 65, pp. 1161-1177.
75. Baudo, F and de Cataldo, F and Gaidano, G. (2004) Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: Data from the Italian registry of acquired hemophilia Haematologica, 88, pp. 759-761.
76. Green, D. (1971) Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide Blood, 37, pp. 381-387.
77. Spero, JA and Lewis, JH and Hasiba, U. (1981) Corticosteroid therapy for acquired F VIII:C inhibitors Br J Haematol, 48, pp. 635-642.
78. Shaffer, LG and Phillips, MD. (1997) Successful treatment of acquired hemophilia with oral immunosuppressive therapy Ann Intern Med, 127, pp. 206-209.
79. Lian, EC and Larcada, AF and Chiu, AY. (1989) Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor Ann Intern Med, 110, pp. 774-778.
80. Green, D and Rademaker, AW and Briet, E. (1993) A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies Thromb Haemost, 70, pp. 753-757.
81. Schwartz, RS and Gabriel, DA and Aledort, LM and Green, D and Kessler, CM. (1995) A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin Blood, 86, pp. 797-804.
82. Schulman, S and Langevitz, P and Livneh, U and Mortinovitz, U and Seligsohn, U and Varon, D. (1996) Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus Thromb Haemost, 76, pp. 344-346.
83. Petrovic, M and Derom, E and Baele, G. (2000) Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies Haematologica, 85, pp. 895-896.
84. Ali, R and Ozcelik, T and Ozkalemkas, F and (2003) Successful treatment of acquired haemophilia with prednisolone therapy Haemophilia, 9, pp. 741-743.
85. Francesconi, M and Korninger, C and Thaler, E and Niessner, H and Höcker, P and Lechner, K. (1982) Plasmapheresis: Its value in the management of patients with antibodies to factor VIII Haemostasis, 11, pp. 79-85.
86. Jansen, M and Schmaldienst, S and Banyai, S and Quehenberger, P and Pabinger, I and Derfler, K. (2001) Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb) Br J Haematol, 112, pp. 91-97.
87. Guillet, B and Kriaa, F and Huisse, MG and Proulle, V and George, C and Tchernia, G. (2001) Protein A sepharose immunoadsorption: Immunological and haemostatic effects in two cases of acquired haemophilia Br J Haematol, 114, pp. 837-844.
88. Ogata, H and Sakai, S and Koiwa, F and (1999) Plasma exchange for acquired hemophilia: A case report Ther Apher, 3, pp. 320-322.
89. Sultan, Y and Kazatchkine, MD and Maisonneuve, P and Nydegger, UE. (1984) Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin Lancet, 2, pp. 765-768.
90. Crenier, L and Ducobu, J and des Grottes, JM and Cerny, J and Delaunoit, C and Capel, P. (1996) Low response to high-dose intravenous immunoglobulin in the treatment of acquired factor VIII inhibitor Br J Haematol, 95, pp. 750-753.
91. Brox, AG and Laryea, H and Pelletier, M. (1998) Successful treatment of acquired factor VIII inhibitors with cyclosporin Am J Hematol, 57, pp. 87-88.
92. Maclean, PS and Tait, RC and Lowe, GD and Walker, ID and McColl, MD. (2003) Successful elimination of factor VIII inhibitor using cyclosporin A Br J Haematol, 122, pp. 1024-1025.
93. Au, WY and Lam, CC and Kwong, YL. (2004) Successful treatment of acquired factor VIII inhibitor with cyclosporin Haemophilia, 10, pp. 98-100.
94. Sallah, S and Wan, JY. (2003) Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophilia Blood, 101, pp. 943-945.
95. Schwedtfeger, R and Hintz, G and Huhn, G. (1991) Successful treatment of a patient with postpartum factor VIII inhibitors with recombinant human interferon alpha-2a Am J Hematol, 45, pp. 190-193.
96. Kain, S and Copeland, TS and Leahy, MF. (2002) Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab) Br J Haematol, 119, pp. 578.
97. Wiestner, A and Cho, HJ and Asch, AS and (2002) Rituximab in the treatment of acquired factor VIII inhibitor Blood, 100, pp. 3426-3428.
98. Stasi, R and Brunetti, M and Stipa, E and Amadori, S. (2004) Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia Blood, 103, pp. 4424-4428.
99. Nemes, L and Pitlik, E. (2000) New protocol for immune tolerance induction in acquired hemophilia Haematologica, 85, pp. 64-68.
100. Kazatchkine, MD and Lacroix-Desmazes, S and Moreau, A and Kaveri, SV. (2000) Idiotypic regulation of anti-factor VIII antibodies Haematologica, 85, pp. 97-99.
101. von Depka, M. (2004) Immune tolerance therapy in patients with acquired hemophilia Hematology, 9, pp. 245-257.
102. Huth-Kuhne, A and Ehrenforth, S and Scharrer, I and Zimmermann, R. (2000) A new theraputic protocol for a rapid FVIII inhibitor elimination in acquired hemophilia Blood, 96, pp. abs 268a.